Quince Therapeutics
QNCX
33 hedge funds and large institutions have $9.55M invested in Quince Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.
25,000% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $7K
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
136% more capital invested
Capital invested by funds: $4.04M → $9.55M (+$5.51M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 32 → 33 (+1)
0% less ownership
Funds ownership: 0.06% → 0.06% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$157K |
| 2 |
SI
Scharf Investments
Los Gatos,
California
|
+$137K |
| 3 |
BlackRock
New York
|
+$134K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$109K |
| 5 |
State Street
Boston,
Massachusetts
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
-$297K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$233K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$161K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$49K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$41.5K |
QNCX Hedge Fund Activity: Q4 2024 in Review
33 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q4 2024, worth a combined $9.55M — up 136% from $4.04M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new QNCX positions and 7 closed out — a net gain of 1 holder — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Shay Capital, adding an estimated $157K. The largest seller was Almitas Capital, exiting entirely with an estimated $297K sold.
- 33 institutional investors held Quince Therapeutics (QNCX) as of Q4 2024, up from 32 in Q3 2024.
- Funds reported $9.55M of Quince Therapeutics stock for Q4 2024, up 136% quarter-over-quarter.
- 8 funds opened new Quince Therapeutics positions in Q4 2024 and 7 closed out, a net change of +1 holder.
- The largest Quince Therapeutics buyer in Q4 2024 was Shay Capital, an estimated $157K added.
- The largest Quince Therapeutics seller in Q4 2024 was Almitas Capital, an estimated $297K sold.
Based on aggregated 13F filings for Q4 2024.